| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
159,588 |
275,693 |
319,053 |
656,089 |
| Total Sell Value |
$13,270,852 |
$23,760,160 |
$27,661,182 |
$61,420,002 |
| Total People Sold |
5 |
6 |
7 |
7 |
| Total Sell Transactions |
10 |
21 |
27 |
56 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-03-11 |
4 |
AS |
$77.68 |
$543,760 |
D/D |
(7,000) |
295,652 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-03-11 |
4 |
OE |
$26.49 |
$185,430 |
D/D |
7,000 |
302,652 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2021-03-05 |
4 |
S |
$76.28 |
$381,400 |
D/D |
(5,000) |
42,840 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2021-03-05 |
4 |
OE |
$26.49 |
$132,450 |
D/D |
5,000 |
47,840 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-03-04 |
4 |
A |
$77.94 |
$7,794 |
D/D |
100 |
295,652 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-02-19 |
4 |
AS |
$83.58 |
$585,060 |
D/D |
(7,000) |
295,552 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-02-19 |
4 |
OE |
$26.49 |
$185,430 |
D/D |
7,000 |
302,552 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-02-18 |
4 |
AS |
$85.08 |
$595,560 |
D/D |
(7,000) |
295,552 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-02-18 |
4 |
OE |
$26.49 |
$185,430 |
D/D |
7,000 |
302,552 |
|
- |
|
| Ho Maykin |
Director |
– • – |
2021-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,350 |
2,350 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-02-17 |
4 |
AS |
$84.54 |
$676,320 |
D/D |
(8,000) |
295,552 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-02-17 |
4 |
OE |
$26.49 |
$211,920 |
D/D |
8,000 |
303,552 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2021-02-16 |
4 |
AS |
$87.41 |
$655,575 |
D/D |
(7,500) |
18,850 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2021-02-16 |
4 |
OE |
$26.49 |
$198,675 |
D/D |
7,500 |
26,350 |
|
- |
|
| Mueller Brian |
EVP, Chief Financial Officer |
• – – |
2021-02-03 |
4 |
D |
$82.82 |
$88,700 |
D/D |
(1,071) |
28,673 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-01-29 |
4 |
AS |
$82.67 |
$688,972 |
D/D |
(8,334) |
295,552 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-01-29 |
4 |
OE |
$26.49 |
$220,768 |
D/D |
8,334 |
303,886 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-01-28 |
4 |
AS |
$82.91 |
$690,889 |
D/D |
(8,333) |
295,552 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-01-28 |
4 |
OE |
$26.49 |
$220,741 |
D/D |
8,333 |
303,885 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-01-27 |
4 |
AS |
$85.49 |
$712,388 |
D/D |
(8,333) |
295,552 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2021-01-27 |
4 |
OE |
$26.49 |
$220,741 |
D/D |
8,333 |
303,885 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2020-12-29 |
4 |
AS |
$88.18 |
$132,270 |
D/D |
(1,500) |
295,552 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2020-12-28 |
4 |
AS |
$88.77 |
$133,155 |
D/D |
(1,500) |
297,052 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2020-10-14 |
4 |
AS |
$79.91 |
$169,489 |
D/D |
(2,121) |
61,281 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2020-10-07 |
4 |
OE |
$26.49 |
$397,350 |
D/D |
15,000 |
66,968 |
|
- |
|
2582 Records found
|
|
Page 15 of 104 |
|
|
1.44 (1.6%) 
